Association between stomatitis and treatment efficacy with novel TROP2-directed antibody drug conjugate (ADC), datopotamab deruxtecan, in patients with metastatic cancer

被引：0
|
作者：
Abelman, Rachel O.
Spring, Laura M.
Ryan, Phoebe K.
Fell, Geoffrey
Juric, Dejan
Heist, Rebecca S.
Bardia, Aditya
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5459
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5459
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
    Bardia, A.
    Messersmith, W. A.
    Kio, E. A.
    Berlin, J. D.
    Vahdat, L.
    Masters, G. A.
    Moroose, R.
    Santin, A. D.
    Kalinsky, K.
    Picozzi, V
    O'Shaughnessy, J.
    Gray, J. E.
    Komiya, T.
    Lang, J. M.
    Chang, J. C.
    Starodub, A.
    Goldenberg, D. M.
    Sharkey, R. M.
    Maliakal, P.
    Hong, Q.
    Wegener, W. A.
    Goswami, T.
    Ocean, A. J.
    ANNALS OF ONCOLOGY, 2021, 32 (06) : 746 - 756
  • [42] Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
    Gray, Jhanelle E.
    Heist, Rebecca S.
    Starodub, Alexander N.
    Camidge, D. Ross
    Kio, Ebenezer A.
    Masters, Gregory A.
    Purcell, W. Thomas
    Guarino, Michael J.
    Misleh, Jamal
    Schneider, Charles J.
    Schneider, Bryan J.
    Ocean, Allyson
    Johnson, Tirrell
    Gandhi, Leena
    Kalinsky, Kevin
    Scheff, Ronald
    Messersmith, Wells A.
    Govindan, Serengulam V.
    Maliakal, Pius P.
    Mudenda, Boyd
    Wegener, William A.
    Sharkey, Robert M.
    Goldenberg, David M.
    CLINICAL CANCER RESEARCH, 2017, 23 (19) : 5711 - 5719
  • [43] Novel Amanitin-Based Antibody-Drug Conjugates Targeting TROP2 for the Treatment of Pancreatic Cancer
    Papacharisi, Eleni
    Braun, Alexandra C.
    Vranic, Marija
    Pahl, Andreas M.
    Hechler, Torsten
    MOLECULAR CANCER THERAPEUTICS, 2025, 24 (04) : 485 - 496
  • [44] OBI-992, a novel TROP2 targeting antibody-drug conjugate, displayed excellent antitumor efficacy in various animal models
    Li, Wan-Fen
    Chiang, Ming-Feng
    Weng, Hao-Cheng
    Yang, Jhih-Jie
    Wu, Hsin-Shan
    Lin, Chun-Jung
    Chiu, Ping-Tzu
    Lai, Ming-Tain
    CANCER RESEARCH, 2024, 84 (06)
  • [45] Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators' choice of chemotherapy (ICC) in previously-treated, inoperable or metastatic hormone-receptor (HR) positive, HER2-negative (HR+/HER2-) breast cancer: TROPION-Breast01
    Bardia, A.
    Kalinsky, K.
    Tsurutani, J.
    Hamilton, E. P.
    Johnston, S.
    Sohn, J.
    Park, K. H.
    Park, Y. H.
    Im, S-A.
    Lee, K. S.
    Dastur, D.
    Haddad, V.
    Khan, S.
    Xu, B.
    Pistilli, B.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S663 - S663
  • [46] OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models
    Li, Wan-Fen
    Chiang, Ming-Feng
    Weng, Hao-Cheng
    Yang, Jhih-Jie
    Wu, Hsin-Shan
    Wu, Szu-Yu
    Chen, Yu-Jung
    Lu, Chi-Huan
    Tu, Jyy-Shiuan
    Hsu, Ren-Yu
    Shia, Chi-Sheng
    Huang, Teng-Yi
    Lai, Ming-Tain
    MOLECULAR CANCER THERAPEUTICS, 2025, 24 (02) : 163 - 175
  • [47] Phase I/II trial of IMMU-132 (isactuzumab govitecan), an anti-Trop-2-SN-38 antibody drug conjugate (ADC): Results in patients with metastatic gastrointestinal (GI) cancers.
    Starodub, Alexander
    Ocean, Allyson J.
    Messersmith, Wells A.
    Picozzi, Vincent J.
    Guarino, Michael J.
    Thomas, Sajeve Samuel
    Bardia, Aditya
    Shah, Manish A.
    Govindan, Serengulam V.
    Maliakal, Pius P.
    Wegener, William A.
    Hamburger, Steven A.
    Sharkey, Robert M.
    Goldenberg, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [48] Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer
    Forero-Torres, A.
    Modi, S.
    Specht, J.
    Miller, K.
    Weise, A.
    Burris, H., III
    Liu, M.
    Krop, I.
    Pusztai, L.
    Kostic, A.
    Li, M.
    Mita, M.
    CANCER RESEARCH, 2017, 77
  • [49] A phase I study of A166, a novel anti-HER2 antibody-drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors
    Lopez, Diana M.
    Barve, Minal
    Wang, Judy
    Bullock, Andrea J.
    Pectasides, Eirini
    Vaishampayan, Ulka
    Spira, Alexander I.
    Ulahannan, Susanna
    Patnaik, Amita
    Sanborn, Rachel E.
    Cicic, Dragan
    Ang, Qiuqing
    Bergonio, Gregory
    Ahnert, Jordi Rodon
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [50] Autophagy modulates intracellular dynamics of [fam-]trastuzumab deruxtecan (DS-8201a), a novel HER2 antibody-drug conjugate (HER2-ADC)
    Abe, Manabu
    Nagata, Motoko
    Koyama, Kumiko
    Yasuda, Satoru
    Hirata, Tsuyoshi
    Kuwahara, Yusuke
    Inaki, Koichiro
    Kasanuki, Naomi
    Minami, Megumi
    Hagihara, Katsunobu
    Wakita, Kenichi
    Slosberg, Eric
    Murakami, Masato
    CANCER RESEARCH, 2019, 79 (13)
12345